Axsome Therapeutics
AXSM
259 hedge funds and large institutions have $3.09B invested in Axsome Therapeutics in 2024 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 97 increasing their positions, 73 reducing their positions, and 26 closing their positions.
73% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 26
33% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 73
6% more funds holding
Funds holding: 244 → 259 (+15)
0% more capital invested
Capital invested by funds: $3.08B → $3.09B (+$15.3M)
0.14% more ownership
Funds ownership: 81.66% → 81.8% (+0.14%)
25% less call options, than puts
Call options by funds: $49.5M | Put options by funds: $66.4M
31% less funds holding in top 10
Funds holding in top 10: 13 → 9 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$56.5M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$36.7M |
| 3 |
Morgan Stanley
New York
|
+$27.2M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$25.6M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$23.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$158M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$38.5M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
-$29.1M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$25.5M |
| 5 |
JFG
Jefferies Financial Group
New York
|
-$19.4M |
AXSM Hedge Fund Activity: Q1 2024 in Review
259 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q1 2024, worth a combined $3.09B — up 0.5% from $3.08B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new AXSM positions and 26 closed out — a net gain of 19 holders — while 97 added to existing stakes and 73 trimmed.
The largest buyer was Macquarie Group, adding an estimated $56.5M. The largest seller was BVF Inc, exiting entirely with an estimated $158M sold.
- 259 institutional investors held Axsome Therapeutics (AXSM) as of Q1 2024, up from 244 in Q4 2023.
- Funds reported $3.09B of Axsome Therapeutics stock for Q1 2024, up 0.5% quarter-over-quarter.
- 45 funds opened new Axsome Therapeutics positions in Q1 2024 and 26 closed out, a net change of +19 holders.
- The largest Axsome Therapeutics buyer in Q1 2024 was Macquarie Group, an estimated $56.5M added.
- The largest Axsome Therapeutics seller in Q1 2024 was BVF Inc, an estimated $158M sold.
Based on aggregated 13F filings for Q1 2024.